ECYT

Recent Articles

16 Pharmaceuticals Stocks to Sell Now

The overall ratings of 16 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More 

26 Pharmaceuticals Stocks to Sell Now

The ratings of 26 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More 

14 Pharmaceuticals Stocks to Sell Now

This week, the ratings of 14 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More 

16 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 16 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More 

12 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 12 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More 

3 Cancer-Fighting Stocks Making Waves in the Markets

After tripping up early in the year, cancer-fighting stocks JUNO, ECYT and SGEN are setting the stage for a comeback rally. More 

ECYT: Why Biopharma Stock Endocyte Is Crashing Hard

Biopharmaceutical company Endocyte (ECYT) saw its stock plunge after its ovarian cancer trial drug failed to help patients. More